Jiangxi Fushine Pharmaceutical Co Ltd banner
J

Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497

Watchlist Manager
Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
Watchlist
Price: 16.08 CNY -2.78% Market Closed
Market Cap: ¥8.7B

Relative Value

The Relative Value of one Jiangxi Fushine Pharmaceutical Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 16.08 CNY, Jiangxi Fushine Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Jiangxi Fushine Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Jiangxi Fushine Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
8.7B CNY 8.9 -31.8 -39.8 -39.8
US
Eli Lilly and Co
NYSE:LLY
969.6B USD 14.9 46.9 31.7 33.7
US
Johnson & Johnson
NYSE:JNJ
588.3B USD 6.3 22 15.3 18.8
CH
Roche Holding AG
SIX:ROG
293.6B CHF 4.8 31.2 13.1 15.3
CH
Novartis AG
SIX:NOVN
250.1B CHF 5.7 23 14.2 18.2
UK
AstraZeneca PLC
LSE:AZN
239.2B GBP 5.5 31.6 17.5 24.6
US
Merck & Co Inc
NYSE:MRK
301.1B USD 4.7 16.6 10.4 12.2
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.4 7.7 9
US
Pfizer Inc
NYSE:PFE
154.1B USD 2.5 20.1 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
123.9B USD 2.6 17.7 7.4 9.1
P/E Multiple
Earnings Growth PEG
CN
J
Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
Average P/E: 24.4
Negative Multiple: -31.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.2
29%
1.1
CH
Novartis AG
SIX:NOVN
23
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
31.6
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.6
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
7%
1.5
US
Pfizer Inc
NYSE:PFE
20.1
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.7
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
J
Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
Average EV/EBITDA: 47
Negative Multiple: -39.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.7
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
CH
Novartis AG
SIX:NOVN
14.2
9%
1.6
UK
AstraZeneca PLC
LSE:AZN
17.5
11%
1.6
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
7%
1.1
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-12%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
J
Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
Average EV/EBIT: 101.6
Negative Multiple: -39.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.7
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.8
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.3
6%
2.6
CH
Novartis AG
SIX:NOVN
18.2
12%
1.5
UK
AstraZeneca PLC
LSE:AZN
24.6
24%
1
US
Merck & Co Inc
NYSE:MRK
12.2
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
8%
1.1
US
Pfizer Inc
NYSE:PFE
10
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.1
-6%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett